Read Time: 2 mins

91/Nine-year real-world experience of SICD implantation at a single centre

Copy Link
Published Online: Oct 3rd 2008
Authors: SA Reddy (Presenting Author) - Papworth, Cambridge, UK; N Kyi - Papworth, Cambridge, UK; AA Grace - Papworth, Cambridge, UK; G Mellor - Papworth, Cambridge, UK
Quick Links:
Article Information

Introduction: The emergence of the subcutaneous implantable cardiac defibrillator (SICD), approved by the FDA in 2012, has been a major breakthrough in cardiac rhythm management. The foremost benefit concerns the lack of necessity to place a lead through the central venous system into the heart, thus avoiding the potential complications of vascular obstruction, thrombosis, infection, cardiac perforation or pneumothorax. This comes at the expense of bradycardia and
anti-tachycardia pacing capability.

SICDs have been implanted at the Royal Papworth Hospital since January 2010. We sought to evaluate the trend of appropriate and inappropriate therapy delivery and device-related complications over time.

Method: Cases were identified through retrospective analysis of institutional databases. Patients’ clinical characteristics, procedural details and complications were recorded. Therapies during
follow-up were classified as appropriate or inappropriate based upon contemporaneous device interrogation. Results were stratified into tertiles by time of implant to compare trends over time.
Continuous variables are presented as mean ± standard deviation, and categorical data as counts or percentages. Analysis and comparisons of continuous data were performed using Student’s t-tests and analysis of variance (ANOVA), whilst categorical data were compared using the χ2 test. A two-tailed probability level of <0.05 was considered significant.

Results: There were 80 SICD implants between January 2010 and January 2019. The mean age at implant was 46 ± 15 years. 50 patients (63%) were male. There was a primary prevention indication in 37 (46%) and secondary prevention in 43 (54%), in keeping with data from other large registries (EFFORTLESS, IDE). Mean implant time was
90 ± 27 minutes.

The overall rate of appropriate therapy was 7.6% per year, whilst inappropriate therapies were delivered at a rate of 8.4% per year. Inappropriate therapies were due to T wave oversensing or incorrect discrimination of atrial arrhythmias. Other device-related complications, defined as undesirable outcomes relating directly to device implantation, occurred in 4 (5%) patients over a total follow up duration of 238 patient-years (1.7% per year).

The distribution of events and complications over approximate time are illustrated in figure 1. (tertile 1: January 2010 to December 2012, n=27; tertile 2: March 2013 to September 2016, n=26; tertile 3: November 2016 to January 2019, n=27). The rate of appropriate therapies varied greatly between tertiles (6.6% per year versus 1.4% versus 27.5%, p<0.05). There was a visual trend towards improvement in rate of inappropriate therapies (10.3% per year versus 6.9% versus 3.4%, p=0.44) and complications (3.7% per year versus 1.4% versus 0%, p=0.43) over time although neither was statistically significant.

There was no significant difference in age, sex, proportion of primary and secondary prevention indications or procedure duration between tertiles.

Conclusion: With evolving improvements in implantation techniques and operator experience the rate of undesirable sequelae resulting from SICD insertion has gradually diminished over time. The overall rate of complications and inappropriate therapies at our centre compares favourably with previously published multi-centre registry data.

Further Resources

Share this Article
Related Content In Arrhythmia
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72